Cergutuzumab amunaleukin (CEA-IL2v) is a CEA-targeted IL-2 variant immunocytokine for combination cancer immunotherapy with immunostimulatory and anti-tumor activities for the study of solid cancers.
Purity:
98.00%
CAS Number:
[1509916-03-3]
Target:
Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted